AR033658A1 - Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d - Google Patents
Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento dInfo
- Publication number
- AR033658A1 AR033658A1 ARP000106143A ARP000106143A AR033658A1 AR 033658 A1 AR033658 A1 AR 033658A1 AR P000106143 A ARP000106143 A AR P000106143A AR P000106143 A ARP000106143 A AR P000106143A AR 033658 A1 AR033658 A1 AR 033658A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- treatment
- pharmaceutical formulation
- acceptable derivative
- antithrombotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Kit de componentes que comprende (a) un antagonista del receptor P2T o un derivado farmacéuticamente aceptable del mismo (componente a) y (b) otro agente antitrombótico o un derivado farmacéuticamente aceptable del mismo (componente b); en el cual cada uno de los componentes (a) y (b) se presenta en una forma (que puede ser igual a la otra o diferente) adecuada para la administración combinada con el otro. Formulación farmacéutica que comprende: (a) un antagonista del receptor P2T o un derivado farmacéuticamente aceptable del mismo y (b) otro agente antitrombótico o un derivado farmacéuticamente aceptable del mismo, mezclado con un adyuvante, diluyente o vehículo farmacéuticamente aceptable. Uso de (a) una formulación farmacéutica que comprende una antagonista del receptor P2T o un derivado farmacéuticamente aceptable del mismo, mezclado con un adyuvante, diluyente o vehículo farmacéuticamente aceptable y (b) una formulación farmacéutica que comprende otro agente antitrombótico o un derivado farmacéuticamente aceptable del mismo, mezclado con un adyuvante, diluyente o vehículo farmacéuticamente aceptable, en terapia. Uso de (a) una formulación farmacéutica que comprende un antagonista del receptor P2T o un derivado farmacéuticamente aceptable del mismo, mezclado con un adyuvante, diluyente o vehículo farmacéuticamente aceptable y (b) una formulación farmacéutica que comprende otro agente antitrombótico o un derivado farmacéuticamente aceptable del mismo, mezclado con un adyuvante, diluyente o vehículo farmacéuticamente aceptable, en el tratamiento de la trombosis. Uso de un antagonista del receptor P2T, o un derivado farmacéuticamente aceptable del mismo, en la elaboración de un medicamento que se ha de utilizar en combinación con otro agente antitrombótico en el tratamiento de la trombosis. La mayoría de los pacientes con infarto agudo de miocardio se tratan en la actualidad empleando un agente trombolítico o un tratamiento quirúrgico con angioplastia coronaria percutánea (PTCA). Se ha demostrado que el uso de estos dos métodos da como resultado un aumento del número de pacientes que logra un despeje aceptable de la arteria coronaria a los 90 minutos y que cuanto mejor sea el flujo en la arteria coronaria afectada, mayor será la supervivencia. Sin embargo, hasta los agentes trombolíticos más eficaces con tratamiento con aspirina y heparina son sólo moderadamente eficaces para lograr el despeje de la arteria coronaria con flujo sanguíneo normal (evaluado como TIMI grado 3) en aproximadamente 50% de los casos. Otra desventaja de los agentes antitrombóticos existentes y combinaciones de los mismos, es que aún no se ha alcanzado la relación óptima riesgo farmacodinámico: beneficio (antitrombótico: antihemostático). Existe la necesidad de una terapia antitrombótica más eficaz. Recientemente se ha demostrado que los antagonistas del receptor P2T (también conocido como P2YADP o P2TAC) ofrecen considerables mejoras con respecto a los demás agentes antitrombóticos. El receptor P2T está implicado fundamentalmente en la mediación en la agregación/activación de plaquetas y es un receptor acoplado da la proteína G. Estos compuestos pueden actuar como agentes antitrombóticos y son provechosos en el tratamiento o profilaxis de angina inestable, apoplejía tromboembólica y enfermedad vascular periférica. También se los puede utilizar en el tratamiento y profilaxis de las secuelas de complicaciones trombóticas de la angioplastia, trombólisis, endarterectomía, cirugía de injerto coronario y vascular, diálisis renal y bypass cardiopulmonar. Además, se los puede emplear en el tratamiento y profilaxis de la coagulación intravascular diseminada, trombosis de venas profundas, preeclamsia, reparación de tejidos con posterioridad al trauma quirúrgico o accidental, vasculitis, arteritis, trombocitemia, isquemia y migrana.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904377A SE9904377D0 (sv) | 1999-12-01 | 1999-12-01 | Pharmaceutical combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033658A1 true AR033658A1 (es) | 2004-01-07 |
Family
ID=20417947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106143A AR033658A1 (es) | 1999-12-01 | 2000-11-21 | Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d |
Country Status (33)
Country | Link |
---|---|
US (2) | US20030032618A1 (es) |
EP (2) | EP1719526A3 (es) |
JP (1) | JP2003515565A (es) |
KR (1) | KR100785953B1 (es) |
CN (1) | CN1402639A (es) |
AR (1) | AR033658A1 (es) |
AT (1) | ATE332698T1 (es) |
AU (1) | AU781691B2 (es) |
BR (1) | BR0016043A (es) |
CA (1) | CA2391161C (es) |
CO (1) | CO5271717A1 (es) |
CY (1) | CY1105211T1 (es) |
CZ (1) | CZ300925B6 (es) |
DE (1) | DE60029340T2 (es) |
DK (1) | DK1237559T3 (es) |
EE (1) | EE05127B1 (es) |
ES (1) | ES2267591T3 (es) |
HK (1) | HK1047893A1 (es) |
HU (1) | HU230890B1 (es) |
IL (1) | IL149495A0 (es) |
IS (1) | IS2841B (es) |
MX (1) | MXPA02004871A (es) |
MY (1) | MY128896A (es) |
NO (1) | NO331215B1 (es) |
NZ (2) | NZ518904A (es) |
PT (1) | PT1237559E (es) |
RU (1) | RU2242232C2 (es) |
SE (1) | SE9904377D0 (es) |
SI (1) | SI1237559T1 (es) |
SK (1) | SK288707B6 (es) |
TW (1) | TWI251491B (es) |
WO (1) | WO2001039781A1 (es) |
ZA (1) | ZA200203707B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
EP1604669A1 (en) * | 2004-06-10 | 2005-12-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of ATP analogues for treatment of cardiovascular diseases |
CA2618187C (en) * | 2005-09-21 | 2011-06-21 | Chong Kun Dang Pharmaceutical Corp. | Novel resinate complex of s-clopidogrel and production method thereof |
US8759316B2 (en) | 2008-05-13 | 2014-06-24 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
WO2009140092A1 (en) | 2008-05-13 | 2009-11-19 | The Medicines Company | Maintenance of platelet inhibition during antiplatelet therapy |
US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
US20130303477A1 (en) | 2008-05-13 | 2013-11-14 | The Medicines Company | Maintenance of Platelet Inhibition During Antiplatelet Therapy |
US20120141468A1 (en) | 2008-05-13 | 2012-06-07 | Lisa Ruderman Chen | Maintenance of platelet inhibition during antiplatelet therapy |
EP2498731B1 (en) * | 2009-11-11 | 2020-01-22 | Chiesi Farmaceutici S.p.A. | Methods of treating or preventing stent thrombosis |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
BR112013020377B1 (pt) | 2011-02-09 | 2022-06-07 | Chiesi Farmaceutici S.P.A. | Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar |
ES2904256T3 (es) | 2013-03-09 | 2022-04-04 | Chiesi Farm Spa | Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos |
EP3641784A1 (en) | 2017-06-23 | 2020-04-29 | Chiesi Farmaceutici S.p.A. | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8826448D0 (en) * | 1988-11-11 | 1988-12-14 | Thrombosis Res Inst | Improvements in/relating to organic compounds |
WO1992017488A1 (en) * | 1991-04-06 | 1992-10-15 | Fisons Plc | Atp analogues |
RU2136693C1 (ru) * | 1993-02-10 | 1999-09-10 | Астра Фармасьютикалз Лимитед | N-алкил-2-замещенные атф и способ их получения |
MA23420A1 (fr) * | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
SE9404196D0 (sv) * | 1994-12-02 | 1994-12-02 | Astra Ab | New antithrombotic formulation |
HU221880B1 (hu) * | 1995-07-11 | 2003-02-28 | Astrazeneca Ab, | Vérlemezke-aggregáció inhibitorok, ezeket tartalmazó gyógyszerkészítmények és előállításuk |
PT1087775E (pt) * | 1998-06-17 | 2005-11-30 | Bristol Myers Squibb Co | Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos |
SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
US6462021B1 (en) * | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
US6696468B2 (en) * | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
US20040067995A1 (en) * | 2002-10-02 | 2004-04-08 | Wong Pancras C. | Novel combination of a factor Xa inhibitor and clopidogrel |
EP1652532A1 (en) * | 2003-07-16 | 2006-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Medicinal composition |
-
1999
- 1999-12-01 SE SE9904377A patent/SE9904377D0/xx unknown
-
2000
- 2000-11-21 AR ARP000106143A patent/AR033658A1/es unknown
- 2000-11-29 AT AT00982033T patent/ATE332698T1/de active
- 2000-11-29 EP EP06075955A patent/EP1719526A3/en not_active Withdrawn
- 2000-11-29 JP JP2001541513A patent/JP2003515565A/ja not_active Ceased
- 2000-11-29 DE DE60029340T patent/DE60029340T2/de not_active Expired - Lifetime
- 2000-11-29 SI SI200030885T patent/SI1237559T1/sl unknown
- 2000-11-29 WO PCT/SE2000/002378 patent/WO2001039781A1/en active IP Right Grant
- 2000-11-29 ES ES00982033T patent/ES2267591T3/es not_active Expired - Lifetime
- 2000-11-29 US US10/148,526 patent/US20030032618A1/en not_active Abandoned
- 2000-11-29 IL IL14949500A patent/IL149495A0/xx unknown
- 2000-11-29 MY MYPI20005578A patent/MY128896A/en unknown
- 2000-11-29 CO CO00091389A patent/CO5271717A1/es not_active Application Discontinuation
- 2000-11-29 RU RU2002117296/15A patent/RU2242232C2/ru active
- 2000-11-29 DK DK00982033T patent/DK1237559T3/da active
- 2000-11-29 CN CN00816374A patent/CN1402639A/zh active Pending
- 2000-11-29 AU AU19109/01A patent/AU781691B2/en not_active Expired
- 2000-11-29 EE EEP200200271A patent/EE05127B1/xx unknown
- 2000-11-29 MX MXPA02004871A patent/MXPA02004871A/es active IP Right Grant
- 2000-11-29 EP EP00982033A patent/EP1237559B1/en not_active Expired - Lifetime
- 2000-11-29 KR KR1020027007026A patent/KR100785953B1/ko not_active IP Right Cessation
- 2000-11-29 PT PT00982033T patent/PT1237559E/pt unknown
- 2000-11-29 BR BR0016043-1A patent/BR0016043A/pt not_active Application Discontinuation
- 2000-11-29 NZ NZ518904A patent/NZ518904A/en not_active IP Right Cessation
- 2000-11-29 SK SK750-2002A patent/SK288707B6/sk not_active IP Right Cessation
- 2000-11-29 CA CA2391161A patent/CA2391161C/en not_active Expired - Lifetime
- 2000-11-29 HU HU0203585A patent/HU230890B1/hu unknown
- 2000-11-29 CZ CZ20021887A patent/CZ300925B6/cs not_active IP Right Cessation
- 2000-11-29 NZ NZ530058A patent/NZ530058A/en not_active IP Right Cessation
- 2000-12-05 TW TW089125873A patent/TWI251491B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 ZA ZA200203707A patent/ZA200203707B/xx unknown
- 2002-05-27 IS IS6398A patent/IS2841B/is unknown
- 2002-05-31 NO NO20022606A patent/NO331215B1/no not_active IP Right Cessation
-
2003
- 2003-01-06 HK HK03100127A patent/HK1047893A1/xx not_active IP Right Cessation
-
2006
- 2006-05-25 US US11/441,278 patent/US20060270607A1/en not_active Abandoned
- 2006-09-05 CY CY20061101267T patent/CY1105211T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033658A1 (es) | Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d | |
CA2288143A1 (en) | Activated protein c formulations | |
ATE72629T1 (de) | Cyclosporin enthaltende pharmazeutische zubereitung. | |
ES2904474T3 (es) | Nueva formulación estable para anticuerpos anti-FXIA | |
KR20030065558A (ko) | 아스피린을 함유하는 의약 조성물 | |
EA199900499A1 (ru) | Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов | |
JP2008517974A (ja) | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 | |
Levy | Hemostatic agents. | |
RU2151602C1 (ru) | Антитромботические негеморрагические композиции на основе гепарина, способ их получения и терапевтические применения | |
Shahab et al. | Vascular toxicity of antineoplastic agents | |
FI952593A (fi) | Hyytymistä estävä aine | |
Bergqvist et al. | Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications | |
Fiorentini et al. | First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer | |
CA2348445A1 (en) | Compositions for the treatment and prevention of cardiovascular diseases | |
EE04966B1 (et) | (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks | |
Dacie et al. | Aminopterin in the treatment of acute leukaemia | |
Griffith et al. | Heparin versus heparin-bishydroxycoumarin anticoagulant therapy: comparison in patients with acute complicated myocardial infarction | |
BR9913846A (pt) | Antagonista receptor de quemocina e ciclosporina em terapia combinada | |
RU2548739C1 (ru) | Способ лечения реперфузионного синдрома у больных сахарным диабетом после реваскуляризирующих операций на артериях нижних конечностей | |
Shrestha et al. | Role of tranexamic acid to reduce blood loss and transfusion of allogeneic blood in the field of surgery | |
US6129932A (en) | Compositions for inhibiting platelet aggregation | |
Dagher et al. | Effect of dextrans on small arterial anastomosis | |
Bergentz et al. | Dextran in vascular surgery | |
CA2465776A1 (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
Avellone et al. | Importance of adjustment of haemorheological and haemocoagulative components in the medical treatment of arteriosclerosis obliterans of the lower limbs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |